Found: 7
Select item for more details and to access through your institution.
A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
- Published in:
- Blood Transfusion (17232007), 2015, v. 13, n. 3, p. 464, doi. 10.2450/2015.0231-14
- By:
- Publication type:
- Article
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E204, doi. 10.1002/ajh.26537
- By:
- Publication type:
- Article
In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
- Published in:
- Frontiers in Immunology, 2019, p. 1, doi. 10.3389/fimmu.2019.02303
- By:
- Publication type:
- Article
Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe.
- Published in:
- Cancers, 2022, v. 14, n. 21, p. 5351, doi. 10.3390/cancers14215351
- By:
- Publication type:
- Article
Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells.
- Published in:
- Cancer Gene Therapy, 2001, v. 8, n. 1, p. 63, doi. 10.1038/sj.cgt.7700274
- By:
- Publication type:
- Article
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
- Published in:
- Journal of Translational Medicine, 2015, v. 13, n. 1, p. 1, doi. 10.1186/s12967-015-0473-5
- By:
- Publication type:
- Article
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article